

PATENT

Case S0328

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Ish K. Khanna, et al.

SERIAL NO.:

09/882,186

FILED:

June 15, 2001

TITLE:

CYCLOALKYL ALKONOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS



GROUP ART UNIT:

EXAMINER:

DATE: June 17, 2002

TECH CENTER 1600/2900

JUN 26 2002

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents and Trademarks
Washington, D.C. 20231
Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

These newly cited documents are as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Rachel A. Polster
Registration No. 47,004
(314) 694-7354 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
800 North Lindbergh Boulevard
St. Louis, Missouri 63167

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)Applicant(s): **Ish K. Khanna, et al.**

Docket No.

S03284

Serial No.

09/882,186

Filing Date

June 15, 2001

Examiner

TBA

Group Art Unit

TBAInvention: **CYCLOALKYL ALKONOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS**I hereby certify that this **Supplemental Information Disclosure Statement**

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Assistant Commissioner for Patents, Washington, D.C. 20231 on

June 17, 2001


(Date)

Edwina Ragan

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET
NO.: S03284

APPLICATION NO.:
09/882,186

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

INVENTOR: Ish K. Khanna et. al

Filed: June 15, 2001

Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
A	5849736	12/15/1998	Wityak, et al.	514	227.8	05/31/1995
B	5665754	09/09/1997	Feldman, et al.	514	397	09/20/1993
C	5773644	06/30/1998	Chen, et al.	562	439	03/27/1997
D	5852210	12/22/1998	Chen, et al.	562	439	03/27/1997
E	5773646	06/30/1998	Chandrakumar, et al.	562	439	03/27/1997
F	3654306	04/04/1972	German, et al.	260	326.5	01/26/1970

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
	Document Number	Date	Country	Class	Subclass		Yes	No
G	WO 00/68195	16.11.2000	UK	C07D	207/16		X	
H	WO 00/33838	15.06.2000	US	A61K	31/435		X	
I	WO 94/27947	08.12.1994	UK	C07C	47/47		X	
J	EP 0747346	11.12.1996	US	C07C	233/18		X	
K	WO 97/19049	29.05.1997	Germany	C07C	229/48		X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	
L	Wityak, et al., "Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic"; <i>Journal of Medicinal Chemistry</i> ; Vol. 43, No. 1, pp 22-26; January 2000
M	Miller, et al., "Discovery of Potent Isoxazoline Glycoprotein Hb/IIIa Receptor Antagonists"; <i>Journal of Medicinal Chemistry</i> ; Vol. 40, No. 1, pp 50-60; 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Duplicate

RECEIVED

TECH CENTER 1600/2500
JUN 26 2002